Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine or psychiatric disorder as determined by the investigator.

Abnormal results of ophthalmologic examination within 3 months prior to dosing self-reported by subject.

Supine systolic blood pressure \> 140 mmHg and/or diastolic blood pressure \> 90 mmHg.

Triglycerides \> 200 mg/dL

Total cholesterol \> 240 mg/dL or LDL \>190 mg/dL or HDL \< 40 mg/dL

Positive urine drug screen at screening or check-in or positive blood alcohol test result at check-in.

Positive hepatitis panel and/or positive HIV test

Administration of a Covid-19 vaccine in the past 28 days prior to dosing

Interpretation of liver ultrasound with presence of fatty liver disease

Study of KBP-7072 in Healthy Male and Female Subjects

What this study is about